19 September 2017
CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).
06 September 2017
Appendix 3B - New issue announcement
30 August 2017
Appendix 4E - Preliminary Final Report 2016/17
08 August 2017
Notice of change of interests of substantial holder
25 July 2017
For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.